Deutsche Bank AG Increases Holdings in Novavax, Inc. (NASDAQ:NVAX)

Deutsche Bank AG lifted its position in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) by 47.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 123,581 shares of the biopharmaceutical company's stock after purchasing an additional 39,787 shares during the quarter. Deutsche Bank AG owned approximately 0.08% of Novavax worth $994,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of NVAX. Spire Wealth Management bought a new position in Novavax in the fourth quarter valued at about $29,000. New Age Alpha Advisors LLC bought a new position in shares of Novavax during the 4th quarter worth approximately $35,000. KBC Group NV boosted its stake in Novavax by 97.0% in the 4th quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 3,917 shares during the period. TigerOak Management L.L.C. bought a new stake in Novavax in the 4th quarter valued at $86,000. Finally, AlphaQuest LLC lifted its position in shares of Novavax by 290.1% during the 4th quarter. AlphaQuest LLC now owns 10,677 shares of the biopharmaceutical company's stock valued at $86,000 after acquiring an additional 7,940 shares during the period. Institutional investors and hedge funds own 53.04% of the company's stock.

Novavax Price Performance

NVAX stock traded up $0.20 during mid-day trading on Friday, hitting $7.39. 9,225,443 shares of the stock were exchanged, compared to its average volume of 7,175,067. The business has a fifty day moving average price of $6.57 and a 200 day moving average price of $7.78. Novavax, Inc. has a 12 month low of $5.01 and a 12 month high of $23.86. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -3.27, a PEG ratio of 2.85 and a beta of 3.21.

Novavax (NASDAQ:NVAX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $2.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $2.22. The firm had revenue of $666.66 million for the quarter, compared to the consensus estimate of $204.08 million. During the same period last year, the firm earned ($1.05) EPS. The company's revenue for the quarter was up 610.3% on a year-over-year basis. As a group, equities analysts forecast that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

Analysts Set New Price Targets

NVAX has been the subject of a number of recent analyst reports. B. Riley reissued a "buy" rating on shares of Novavax in a research report on Monday, May 19th. JPMorgan Chase & Co. decreased their price target on Novavax from $9.00 to $7.00 and set an "underweight" rating for the company in a research report on Friday, May 9th. TD Cowen raised Novavax to a "hold" rating in a research report on Thursday, February 27th. Finally, BTIG Research began coverage on Novavax in a research report on Friday, February 28th. They issued a "buy" rating and a $19.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $19.00.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.